The goal of this study was to assess the plasma level of sclerostin and DKK-1 in patients with GD and correlate it with the degree of bone involvement, including bone pain, bone marrow infiltration, Erlenmeyer (EM) flask deformity, and osteoporosis. This evidence concerns the gene SOST and osteoporosis.